Abstract Number: 270 • 2013 ACR/ARHP Annual Meeting
Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a 12-Week Pooled Post-Hoc Analysis For Efficacy
Background/Purpose: Interleukin-1β (IL-1β) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA), a severe disabling subtype of JIA characterized by arthritis…Abstract Number: 271 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study
Background/Purpose: Interleukin-1β (IL-1β) is a key cytokine in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective fully human anti-IL-1β monoclonal antibody,…Abstract Number: 272 • 2013 ACR/ARHP Annual Meeting
Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis characterized by spiking fever, rash, and arthritis. Tocilizumab (TCZ), an anti-IL-6 receptor…Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…Abstract Number: 274 • 2013 ACR/ARHP Annual Meeting
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis that is characterized by a spiking fever, rash, and arthritis. About 7%…Abstract Number: 275 • 2013 ACR/ARHP Annual Meeting
Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab
Background/Purpose: Tocilizumab (TCZ), anti-human interleukin-6 receptor monoclonal antibody, was the first biologic agent used in the treatment of systemic juvenile idiopathic arthritis (sJIA) in Japan.…Abstract Number: 276 • 2013 ACR/ARHP Annual Meeting
Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From The Tender Trial
Background/Purpose: A phase 3 trial (TENDER) demonstrated the efficacy of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA).1,2 The…Abstract Number: 277 • 2013 ACR/ARHP Annual Meeting
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (pJIA) among North American pediatric rheumatologists. Understanding the comparative…Abstract Number: 278 • 2013 ACR/ARHP Annual Meeting
Results Of a 24 Month Extension Study In Patients Who Participated In The Trial Of Early Aggressive Therapy In Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: The Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT-JIA) was a double-blind, randomized, placebo-controlled trial in 85 patients with onset of…Abstract Number: 279 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 To <4 Years Or ≥4 Years Weighing <15 Kg
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US,…Abstract Number: 240 • 2013 ACR/ARHP Annual Meeting
Longitudinal Femorotibial Cartilage Thickness Increase In Young Athletes At The End Of Adolescence
Background/Purpose: Anterior or posterior cruciate ligament (ACL/PCL) ruptures are thought to lead to early knee osteoarthritis (KOA) and thus considered scientifically valuable “models” of pre-radiographic…Abstract Number: 241 • 2013 ACR/ARHP Annual Meeting
Exploratory Factor Analysis Of a Parsimonious Medial Cartilage Damage Index Reveals One Factor Associated With Radiographic Severity and Symptoms: Data From The Osteoarthritis Initiative
Background/Purpose: The cartilage damage index (CDI) is a parsimonious method of measuring articular cartilage approximating regional cartilage volume based on 18 locations within the knee,…Abstract Number: 242 • 2013 ACR/ARHP Annual Meeting
Elevated Systemic Blood Pressure Is Associated With Increased Prevalent Knee Osteoarthritis and Knee Pain: Data From The Osteoarthritis Initiative
Background/Purpose: Epidemiologic studies have linked osteoarthritis (OA) to atheromatous vascular disease, both age-related diseases. Systemic hypertension (HTN) is an important risk factor for cardiovascular disease…Abstract Number: 243 • 2013 ACR/ARHP Annual Meeting
The Association Between Metabolic Syndrome and Hand Osteoarthritis – Data From The Framingham Study
Background/Purpose: Metabolic factors may have a negative effect on cartilage, and may be especially relevant in the pathogenesis of hand OA. Our aim was to…Abstract Number: 244 • 2013 ACR/ARHP Annual Meeting
Association Between Serum Adipokine Levels and Extent Of Symptomatic Joint Involvement In Hip and Knee Osteoarthritis
Background/Purpose: Osteoarthritis (OA) has not traditionally been considered a systemic joint disease. However, a growing body of evidence suggests that OA cannot solely be accounted…